Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Attogene Corporation
Profile last edited on: 1/27/21      CAGE: 5K6J2      UEI: M5VSPH6FK6D6

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2012
First Award
2019
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3913 Todd Lane Suite 310
Austin, TX 78744
   (512) 333-1330
   sales@attogene.com
   www.attogene.com
Location: Single
Congr. District: 35
County: Travis

Public Profile

The firm is described on the website as addressing development of high quality products to support pathologists and biological and environmental scientists.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$570,000
Phase II Dollars
$0
Total Awarded
$570,000

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 1 NIH $229,975
Project Title: Convenient rapid and portable tool for the detection of ribonucleases
2023 1 NIH $248,848
Project Title: PA22176, SBIR, Phase I, Lateral Flow Assay to Detect Malaria
2020 1 DOC $120,000
Project Title: Novel assay for the detection of water-born algae toxins
2020 1 NSF $225,000
Project Title: Development of a portable, sensitive, user-friendly electrochemical biosensor for detecting Pesticide residues
2019 1 NIH $225,000
Project Title: Development of a rapid diagnostic assay for Myasthenia Gravis

Key People / Management

  Lance P Ford -- Founder, President and CEO

  Soroush Ayrempour -- Medical Director

  Joseph Francis Krebs

Company News

There are no news available.